
    
      The duration of the study for one patient in the dose escalation phase of the study will
      include a screening period of up to 3 weeks and a 4-week treatment cycle(s). The patients may
      continue treatment until disease progression, unacceptable toxicity, or willingness to stop,
      followed by a minimum of 30-day follow-up. The study will also include 2 expansion cohorts.
      If a patient treated in dose escalation part or in an expansion cohorts, continues to benefit
      from the treatment at the time of Clinical Study Report, the patient can continue study
      treatment for a maximum of 1 year and will continue to undergo all assessments as per the
      study flowchart. Such patients will be followed at least until 30 days after the last IMP
      administration.
    
  